companies / akribion-therapeutics-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-02 json
| total_raised | 8,640,0008.6M | ○ |
|---|---|---|
| founded | 2022 | |
| hq | Zwingenberg, Germany | |
| industry | unknown | |
| stage | seed |
Akribion develops the G-dase E RNA-guided nuclease for programmable cell depletion in precision oncology. It targets clinicians treating HPV-induced head-and-neck cancers initially, with broader oncology potential. Differentiator: single-nucleotide specificity and rapid retargeting via gRNA exchange.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-02-15 | seed | 8,640,0008.6M | null | ○ |
PHP 8.2.31, WordPress 6.9.4, Apache HTTP Server 2.4.67, Magnific Popup 8.45.1, UNIX, MySQL, apache 2.4.67, jquery 3.7.1
| fact | status | src |
|---|---|---|
| Seed, $8.6M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |